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EORTC QLQ-C30Abstract Background: In KEYNOTE-002, pembrolizumab significantly prolonged
progression-free survival and was associated with a better safety profile compared with chemo-
therapy in patients with advanced melanoma that progressed after ipilimumab. We present
health-related quality of life (HRQoL) outcomes from KEYNOTE-002.
Methods: Patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every
3 weeks (Q3W) or investigator-choice chemotherapy. HRQoL was assessed using the Euro-
pean Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-
Core 30 instrument. A constrained longitudinal data analysis model was implemented to
assess between-arm differences in HRQoL scores. The study is registered with
ClinicalTrials.gov, number NCT01704287.
Results: Of the 540 patients enrolled, 520 were included in the HRQoL analysis. Baseline
global health status (GHS) was similar across treatment arms. Compliance rates at week 12
were 76.6% (nZ 108), 82.3% (nZ 121), and 86.4% (nZ 133) for the control, pembrolizumab
2 mg/kg Q3W, and pembrolizumab 10 mg/kg Q3W arms, respectively. From baseline to week
12, GHS/HRQoL scores were maintained to a higher degree in the pembrolizumab arms
compared with the chemotherapy arm (decrease of 2.6 for each pembrolizumab arm versus
9.1 for chemotherapy; PZ 0.01 for each pembrolizumab arm versus chemotherapy). Fewer
patients treated with pembrolizumab experienced deterioration in GHS at week 12 (31.8% for
pembrolizumab 2 mg/kg, 26.6% for 10 mg/kg, and 38.3% for chemotherapy), with similar
trends observed for the individual functioning and symptoms scales.
Conclusions: HRQoL was better maintained with pembrolizumab than with chemotherapy in
KEYNOTE-002, supporting the use of pembrolizumab in patients with ipilimumab-refractory
melanoma.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Engagement between the programmed death 1 (PD-1)
receptor and its ligands, PD-L1 and PD-L2 [1], inhibits
T-cell-receptor signalling, ultimately leading to down-
regulation of the T-cell-mediated antitumour immune
response [2e4]. The expression of PD-1 ligands by some
tumours enables them to avoid surveillance and thus
destruction by the innate immune system [5].
PD-1 inhibitors have shown promising activity against
a growing list of cancer types [6]. Pembrolizumab and
nivolumab are approved anti-PD-1 therapies for the
treatment of advanced melanoma [7]. Pembrolizumab, a
monoclonal antibody that directly blocks binding between
PD-1 and PD-L1/PD-L2 [8], is approved worldwide for
the treatment of patients with unresectable or metastatic
melanoma, in the United States and European Union for
patients with metastatic, PD-L1-expressing non-small-cell
lung cancer, and in the United States for recurrent or
metastatic head and neck squamous cell carcinoma with
disease progression on or after platinum-containing
chemotherapy [8,9]. Pembrolizumab first demonstrated
durable antitumour activity and manageable safety inpatients with ipilimumab-naive and ipilimumab-treated
advanced melanoma in the phase Ib KEYNOTE-001
study [10]. In the subsequent phase II KEYNOTE-002
trial of patients with advanced melanoma who pro-
gressed on ipilimumab and, ifBRAFV600 mutant, a BRAF
and/or MEK inhibitor, pembrolizumab significantly pro-
longed progression-free survival (PFS) compared with
investigator-choice chemotherapy [11]. In the phase III
KEYNOTE-006 study, pembrolizumab provided supe-
rior overall survival (OS) and PFS and improved safety
compared with ipilimumab in patients with ipilimumab-
naive advanced melanoma who received one or no prior
therapy [12]. These findings led to the approval of pem-
brolizumab worldwide for both ipilimumab-refractory
and ipilimumab-naive melanoma. Nivolumab is also
approved worldwide for advanced melanoma on the basis
of phase III trials in patients with ipilimumab-refractory
[13] and ipilimumab-naive [14,15] metastatic melanoma.
Although outcomes for cancer patients are generally
measured in terms of survival and response, patient-
reported outcomes (PROs) and health-related quality of
life (HRQoL) are of high relevance to the patient [16].
Here, we report analyses of HRQoL for patients with
D. Schadendorf et al. / European Journal of Cancer 67 (2016) 46e5448advanced melanoma treated with pembrolizumab
compared with investigator’s choice of chemotherapy in
KEYNOTE-002.
2. Methods
2.1. Study design
Details of the international, randomised phase II
KEYNOTE-002 study (ClinicalTrials.gov, number
NCT01704287) were published previously [11]. Briefly,
patients with unresectable stage III or IV melanoma,
disease progression after two or more prior ipilimumab
doses, and previous BRAF and/or MEK inhibitor
therapy (BRAFV600 mutant only) were randomly allo-
cated 1:1:1 to pembrolizumab 2 mg/kg every 3 weeks
(Q3W), pembrolizumab 10 mg/kg Q3W, or investigator-
choice chemotherapy (paclitaxel plus carboplatin,
paclitaxel, dacarbazine, carboplatin, or temozolomide).
Treatment was continued until disease progression, un-
acceptable toxicity, or other reason.
2.2. Assessments
Tumour response was assessed at baseline, at week 12,
then every 6 weeks until week 48, and every 12 weeks
thereafter per Response Evaluation Criteria In Solid
Tumours, version 1.1 (RECIST v1.1), by central imag-
ing vendor review. All patients completed the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality-of-Life Questionnaire-Core 30 in-
strument (QLQ-C30) before all clinical procedures at
baseline, weeks 3, 6, 12, 24, and 36, at treatment
discontinuation, and during safety follow-up.
2.3. Statistical analyses
PROs were an exploratory end-point with a prespecified
statistical analysis before database lock. Analyses were
performed in patients who received one or more doses of
study medication and who completed one or more PRO
assessments (PRO full analysis set [FAS]). An instrument
was considered complete if at least one valid score was
available. The PRO compliance rate was defined as the
proportion of patients who completed the instrument
among those expected to complete it at each visit,
excluding those missing by design (e.g. death, discontin-
uation of treatment, instrument translations not available,
or no visit scheduled). The PRO completion rate was
defined as the proportion of patients who completed the
instrument among the PRO FAS population.
Because >50% of patients in the control group were
expected to have disease progression at week 12 based
on historical data, PRO score changes from baseline
were evaluated at week 12. Linear transformation was
applied to standardise raw scores to a range of 0e100. A
score change of at least 10 points was consideredclinically meaningful and was used to define deteriora-
tion and improvement [17]. A constrained longitudinal
data analysis model was used to assess the effect of
treatment and disease progression on PRO score
changes. The primary statistical method was a mixed-
effect model with multiple imputation based on the
missing at random assumption, with sensitivity analysis
based on missing pattern and control-based multiple
imputation. A summary of the proportion of patients
with improvement, stability, and deterioration in global
health status (GHS)/HRQoL was also based on the
missing at random assumption.3. Results
3.1. Patients
In total, 540 patients were randomly assigned to pem-
brolizumab 2 mg/kg (nZ 180), pembrolizumab 10 mg/kg
(n Z 181), or chemotherapy (n Z 179). Patient baseline
characteristics, which have been published in detail else-
where [11], were well balanced across the three arms. In
brief, patients ranged in age between 15 and 89 years, with
a median of 62, 60, and 63 years for the pembrolizumab
2 mg/kg, pembrolizumab 10 mg/kg, and chemotherapy
arms, respectively, and a male:female ratio of 1.4, 1.5, and
1.8, respectively. The proportions of patients were similar
between the arms for Eastern Cooperative Oncology
Group performance status 0 (54%, 54%, and 55%) and
presence of BRAFV600 mutation (24%, 22%, and 23%).3.2. Completion and compliance rate of the EORTC
QLQ-C30
Of the 540 patients enrolled, 520 received1 dose of study
treatment and completed the EORTC QLQ-C30 at least
once and were eligible for analysis: 176 in the pem-
brolizumab 2 mg/kg arm, 177 in the pembrolizumab
10 mg/kg arm, and 167 in the chemotherapy arm. The
EORTC QLQ-C30 completion rate decreased over time,
along with the number of patients available to complete
for all three treatment arms (Table 1). The most common
reasons for non-completion were discontinuation because
of disease progression or adverse events (AEs), death, and
site administrative error (Supplemental Table 1). A higher
proportion of patients in the chemotherapy arm did not
complete the questionnaire at weeks 3, 6, and 12 because
of disease progression.
Compliance rates for the control, pembrolizumab
2 mg/kg Q3W, and pembrolizumab 10 mg/kg Q3W arms
were 93.4% (n Z 156), 96.0% (n Z 169), and 96.0%
(nZ 170), respectively, at baseline, and 76.6% (nZ 108),
82.3% (n Z 121), and 86.4% (n Z 133) at week 12.
Compliance rates decreased in all groups at weeks 24 and
36, particularly among the control group (Table 1 and
Supplemental Table 1).
Table 2
Baseline and week 12 global health status scale scores of the EORTC QLQ-C30 and change from baseline at week 12.
Treatment arm Baseline Week 12 Change from baseline
least squares mean (95% CI)
n Mean  SD n Mean  SD
Pembrolizumab 2 mg/kg Q3W 169 66.2  22.1 120 66.3  23.0 2.6 (6.2, 1.0)a
Pembrolizumab 10 mg/kg Q3W 168 62.9  23.6 132 64.3  22.8 2.6 (6.0, 0.9)a
Chemotherapy 155 64.0  21.9 108 59.0  23.2 9.1 (12.9, 5.4)
CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30;
Q3W, every 3 weeks; SD, standard deviation.
a P Z 0.01 versus chemotherapy.
Table 1
The rate of compliancea and number of patients available to complete the EORTC QLQ-C30 instrument at each visit.
Time point Category Pembrolizumab
2 mg/kg Q3W
(n Z 176)
Pembrolizumab
10 mg/kg Q3W
(n Z 177)
Chemotherapy
(n Z 167)
Baseline Expected to complete, n 176 177 167
Completed, n 169 170 156
Compliance rate in those expected to complete, % 96.0 96.0 93.4
Completion rate in total population, % 96.0 96.0 93.4
Week 3 Expected to complete, n 172 174 163
Completed, n 161 157 133
Compliance rate in those expected to complete, % 93.6 90.2 81.6
Completion rate in total population, % 91.5 88.7 79.6
Week 6 Expected to complete, n 162 165 151
Completed, n 144 146 122
Compliance rate in those expected to complete, % 88.9 88.5 80.8
Completion rate in total population, % 81.8 82.5 73.1
Week 12 Expected to complete, n 147 154 141
Completed, n 121 133 108
Compliance rate in those expected to complete, % 82.3 86.4 76.6
Completion rate in total population, % 68.8 75.1 64.7
Week 24 Expected to complete, n 104 112 109
Completed, n 82 101 37
Compliance rate in those expected to complete, % 78.8 90.2 33.9
Completion rate in total population, % 46.6 57.1 22.2
Week 36 Expected to complete, n 69 75 72
Completed, n 33 39 21
Compliance rate in those expected to complete, % 47.8 52.0 29.2
Completion rate in total population, % 18.8 22.0 12.6
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30; Q3W, every 3 weeks.
a Compliance was defined as the proportion of patients who completed the EORTC QLQ-C30 among those who were expected to complete it at
each visit, excluding those missing by design (e.g. death, discontinuation due to an adverse event).
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The baseline GHS/HRQoL score was similar across the
three treatment arms (mean 66.2, 62.9, and 64.0 in the
pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, and
chemotherapy arms, respectively) (Table 2). Treatment
with pembrolizumab resulted in significantly smaller
decrements in the GHS/HRQoL scale score compared
with chemotherapy, with no difference between pem-
brolizumab arms (Table 2). The least squares mean
(95% confidence interval) change from baseline at
week 12 was 2.6 (6.15 to 0.96) for pembrolizumab
2 mg/kg, e2.6 (5.99 to 0.89) for pembrolizumab
10 mg/kg, and 9.1 (12.86 to 5.39) for chemotherapy
(Table 2). The differences between pembrolizumab and
chemotherapy were statistically significant (P Z 0.011for pembrolizumab 2 mg/kg versus chemotherapy and
0.009 for pembrolizumab 10 mg/kg versus chemo-
therapy) (Table 2). A similar trend of score change dif-
ferences was observed in a sensitivity analysis, in which
the imputation rule was based on the reason for miss-
ingness or control-based multiple imputation (data not
shown).
In addition to the GHS/HRQoL score, patients in the
two pembrolizumab arms had consistently smaller lon-
gitudinal score changes from baseline to week 12 across
functional scales, including physical, role, cognitive,
social, and emotional functions, and across symptoms
scales including fatigue, nausea/vomiting, pain, dysp-
noea, insomnia, appetite loss, constipation, and diar-
rhoea (Table 3).
Table 3
Change from baseline to week 12 in scores for the GHS/quality of life and functional and symptom scales of the EORTC QLQ-C30 questionnaire
for the full analysis set population.a
Pembrolizumab 2 mg/kg Q3W (n Z 176) Pembrolizumab 10 mg/kg Q3W (n Z 177) Chemotherapy (n Z 167)
Mean Upper limit Lower limit Mean Upper limit Lower limit Mean Upper limit Lower limit
GHS and functional scales
GHS/quality of life 2.6 1.0 6.1 2.6 0.9 6.0 9.1 5.4 12.9
Physical functioning 4.2 1.0 7.5 2.8 0.4 5.9 5.2 1.8 8.6
Role functioning 4.7 0.2 9.3 5.8 1.3 10.2 9.3 4.5 14.1
Emotional functioning 0.2 3.3 2.9 0.60 3.6 2.4 1.1 2.2 4.4
Cognitive functioning 2.1 0.8 5.1 1.4 1.5 4.2 3.5 0.4 6.6
Social functioning 2.7 1.3 6.7 2.4 1.5 6.3 4.7 0.5 8.9
Symptom scales
Fatigue 3.3 7.1 0.5 4.7 8.4 1.0 7.0 11.0 3.0
Nausea and vomiting 1.5 4.3 1.2 1.4 4.0 1.3 5.2 8.1 2.3
Pain 0.8 4.9 3.2 1.2 5.0 2.7 3.4 7.7 0.8
Dyspnoea 1.7 5.8 2.5 0.1 3.9 4.1 6.8 11.2 2.5
Insomnia 0.6 4.1 5.4 1.5 6.0 3.1 2.2 7.2 2.8
Appetite loss 1.7 3.2 6.6 1.4 6.1 3.4 3.3 8.4 1.9
Constipation 2.5 6.7 1.7 3.9 8.0 0.1 5.1 9.5 0.6
Diarrhoea 1.7 1.4 4.8 0.0 3.0 2.9 1.4 4.6 1.9
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30; GHS, global health
status; Q3W, every 3 weeks.
a For health-related quality of life or functions, a higher score denotes better quality of life or functions and a higher negative score denotes
worse quality of life or functions. For symptoms, a higher score denotes worse symptoms and a higher negative score denotes better symptoms.
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HRQoL score at different time points for each of the
treatment groups, without any imputation of missing
data (Fig. 1). As with the longitudinal analysis, the
baseline GHS/HRQoL score was similar between the
three groups. For the control group, the GHS/HRQoL
score declined from baseline to week 12; there was a
sharp decrease at week 3. For both of the pem-
brolizumab arms, scores were relatively stable at
different time points. Data at weeks 24 and 36 should
be interpreted cautiously because of the limited sampleEO
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3.4. PRO responder analysis at week 12
The rates of improved, stable, or deteriorated HRQoL
at week 12, defined as a change from baseline of
10 points, are presented in Fig. 2. Approximately
7e12% fewer patients in the pembrolizumab arms63keeW42keeW
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Fig. 2. Proportions of improved, stable, and deteriorated health-related quality of life as assessed by changes from baseline of 10 points
at week 12 in the global health status and functional and symptom scales of the European Organisation for Research and Treatment of
Cancer Quality-of-Life Questionnaire-Core 30 instrument. For each plot, A Z pembrolizumab 2 mg/kg every 3 weeks (Q3W),
B Z pembrolizumab 10 mg/kg Q3W, and C Z chemotherapy.
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in the chemotherapy arm (31.8% in the pembrolizumab
2 mg/kg arm, 26.6% in the pembrolizumab 10 mg/kg
arm, and 38.3% in the control arm). The two pem-
brolizumab arms had consistently smaller proportions
of deteriorated and generally larger proportions of sta-
ble or improved scores for different functional and
symptoms scales compared with the control arm. These
responder analyses are consistent with the longitudinal
analysis showing that mean GHS/HRQoL is better at
week 12 for patients in the pembrolizumab arms
compared with the control arm. Similar results were
observed at other time points, including weeks 3 and 6
(data not shown). This finding persisted when consid-
ering each subdomain separately or when using more
stringent thresholds of 15 and 20 points (data not
shown).Fig. 3. Global health status/health-related quality-of-life scores of
the European Organisation for Research and Treatment of Cancer
Quality-of-Life Questionnaire-Core 30 instrument over time in
patients with and without disease progression. The follow-up visit
was 30 d after discontinuation. Abbreviations: LS, least squares;
CI, confidence interval; PRO, patient-reported outcome.3.5. ‘Progression effect’ analysis
Across treatment arms, patients without disease pro-
gression had similar GHS/HRQoL scores at baseline
and at the most recent assessment before treatment
discontinuation (Fig. 3). Conversely, GHS/HRQoL
scores decreased by approximately 10 points at the time
of discontinuation. Scores were generally worse in the
presence of disease progression than in its absence,
among the different treatment arms and for the overallpopulation. A similar trend of association was observed
when using the observed data without any imputation
(Supplemental Fig. 1). These results suggested that dis-
ease progression has a negative impact on patients’
HRQoL, regardless of the treatment received.
We also performed a post hoc analysis of the joint
effect of treatment and disease progression on HRQoL.
Chemotherapy* (n = 17)
Pembrolizumab 10 mg/kg (n = 69)
Pembrolizumab 2 mg/kg (n = 56)
Chemotherapy* (n = 150)
Pembrolizumab 10 mg/kg (n = 108)
Pembrolizumab 2 mg/kg (n = 120)
P = 0.0004
P = 0.9459
P = 0.5356
P <0.0001
P = 0.0536
P = 0.1919
Change from Baseline
Without disease progression
With disease progression
–20 –10 0 10
Fig. 4. Impact of disease progression and treatment arm on change from baseline in global health status/health-related quality of life at
week 12. *P < 0.05 for change from baseline to week 12.
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progression had a negative effect on the GHS/HRQoL
score, but the decrease was statistically significant for
the chemotherapy arm only. Among patients treated
with pembrolizumab without progression, there was a
minimal change in the GHS/HRQoL score (PZ 0.5356
for the 2 mg/kg arm; PZ 0.9459 for the 10 mg/kg arm).
For patients treated with chemotherapy, there was an
estimated 8.95-point decrease from baseline among pa-
tients without progression (P Z 0.0004) and a 14.4-
point decrease among those with progression
(P < 0.0001). Across treatment arms, disease progres-
sion was estimated to induce a 5.46-point decrease in the
GHS/HRQoL score from baseline to week 12
(P Z 0.009).
4. Discussion
For metastatic melanoma, the choice of systemic ther-
apy is influenced not only by efficacy and symptom
control but also by HRQoL [18e20]. KEYNOTE-002
enrolled patients with ipilimumab-refractory advanced
melanoma, with two-thirds of patients having had at
least two previous lines of treatment [11]. The results of
the present PRO analysis for KEYNOTE-002 never-
theless indicate that the patients treated with pem-
brolizumab maintained HRQoL to a greater degree
compared with chemotherapy. The results were consis-
tent following sensitivity analyses, including using
different imputation methods on missing PRO data and
analysing only the observed data at different time points
without any imputation. Furthermore, they are sup-
ported by the finding that the pembrolizumab-treated
patients had consistently smaller score changes from
baseline to week 12 for different functional andsymptoms scales compared with their chemotherapy-
treated counterparts.
In addition, consistently smaller proportions of dete-
riorated, and larger proportions of stable or improved
GHS/HRQoLand functional and symptoms scales scores
were observed for the two pembrolizumab arms
compared with the chemotherapy arm. GHS/HRQoL
deteriorated by10 points in 7e12% fewer patients in the
pembrolizumab arms than in the chemotherapy arm be-
tween baseline and week 12. These results are consistent
with the finding that mean GHS/HRQoL was better at
week 12 for pembrolizumab-treated patients than for
those on chemotherapy. Finally, disease progression was
found to have a negative impact on GHS/HRQoL
regardless of the therapeutic modality, as has been
described for other systemic therapies [20,21].
Taken together, these findings suggest that pem-
brolizumab is well tolerated and either improves or
maintains HRQoL or symptoms when compared with
chemotherapy. Furthermore, they support the reported
clinical benefit of pembrolizumab over chemotherapy
with respect to PFS [11]. Therefore, delaying disease
progression or extending PFS appears to help to main-
tain or improve HRQoL in these patients.
Associations between improvements in HRQoL and
therapeutics that confer survival benefits (PFS and OS)
in BRAFV600 mutant metastatic melanoma have been
reported previously. A better preservation of HRQoL
appeared to be associated with delayed disease pro-
gression in a phase III study of dabrafenib and trame-
tinib versus dabrafenib monotherapy (the COMBI-
d trial) [20], and similar findings were reported in a
phase III study of trametinib versus chemotherapy (the
METRIC study) [19]. Similarly, in the COMBI-v study
of dabrafenib and trametinib versus dabrafenib
D. Schadendorf et al. / European Journal of Cancer 67 (2016) 46e54 53monotherapy, the combination therapy was associated
with improved HRQoL compared with dabrafenib
monotherapy [21].
These and the present findings raise the question of
whether PROs can be a surrogate marker for prognosis in
the oncology setting. In a global analysis ofmultitrial data
across 11 cancer sites,Quinten et al. [22] found that at least
one baseline HRQoL domain yielded prognostic infor-
mation for each cancer site additional to those providedby
clinical and sociodemographic variables, suggesting that
baselineHRQoLdata can add complementary prognostic
value to standard clinical variables. In a systematic review
of the literature, Montazeri [23] found a significant and
positive relationship between certain HRQoL parameters
and survival among patients with various cancer types,
including melanoma. Further studies are needed to
establish a definitive prognostic relationship between
HRQoL measures and clinical outcome in advanced
melanoma patients treated with pembrolizumab.
4.1. Study limitations
These findings should be considered in the light of
several limitations. Firstly, clinical trial populations may
differ from melanoma patients in the general population
with regard to motivation, the likelihood of PRO
reporting, and ability to withstand treatment-related
AEs. Secondly, the number of patients without disease
progression in the chemotherapy arm was low compared
with those without progression in the pembrolizumab
arms. Thus, the HRQoL outcomes reported here are
likely associated with tumour progression in addition to
chemotherapy-related side-effects. Thirdly, this was a
partially blinded study; assignment to the chemotherapy
arm versus one of the two pembrolizumab arms was
open label. However, the PRO results are consistent
across different domains and different sensitivity ana-
lyses, suggesting the results are unlikely to be biased
because of the partially blinded design.
5. Conclusions
HRQoL was maintained to a greater degree with pem-
brolizumab than with investigator-choice chemotherapy
in patients with ipilimumab-refractory melanoma.
Approximately 10% more patients treated with chemo-
therapy than with pembrolizumab experienced deterio-
ration in HRQoL by week 12. Regardless of treatment,
HRQoL decreased in patients who experienced disease
progression. These data support the use of pem-
brolizumab in this patient population.
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